Literature DB >> 21683689

Tumor-targeting magnetic lipoplex delivery of short hairpin RNA suppresses IGF-1R overexpression of lung adenocarcinoma A549 cells in vitro and in vivo.

Chunmao Wang1, Chao Ding, Minjian Kong, Aiqiang Dong, Jianfang Qian, Daming Jiang, Zhonghua Shen.   

Abstract

Liposomal magnetofection potentiates gene transfection by applying a magnetic field to concentrate magnetic lipoplexes onto target cells. Magnetic lipoplexes are self-assembling ternary complexes of cationic lipids with plasmid DNA associated with superparamagnetic iron oxide nanoparticles (SPIONs). Type1 insulin-like growth factor receptor (IGF-1R), an important oncogene, is frequently overexpressed in lung cancer and mediates cancer cell proliferation and tumor growth. In this study, we evaluated the transfection efficiency (percentage of transfected cells) and therapeutic potential (potency of IGF-1R knockdown) of liposomal magnetofection of plasmids expressing GFP and shRNAs targeting IGF-1R (pGFPshIGF-1Rs) in A549 cells and in tumor-bearing mice as compared to lipofection using Lipofectamine 2000. Liposomal magnetofection provided a threefold improvement in transgene expression over lipofection and transfected up to 64.1% of A549 cells in vitro. In vitro, IGF-1R specific-shRNA transfected by lipofection inhibited IGF-1R protein by 56.1±6% and by liposomal magnetofection by 85.1±3%. In vivo delivery efficiency of the pGFPshIGF-1R plasmid into the tumor was significantly higher in the liposomal magnetofection group than in the lipofection group. In vivo IGF-1R specific-shRNA by lipofection inhibited IGF-1R protein by an average of 43.8±5.3%; that by liposomal magnetofection inhibited IGF-1R protein by 43.4±5.7%, 56.3±9.6%, and 72.2±6.8%, at 24, 48, and 72 h, respectively, after pGFPshIGF-1R injection. Our findings indicate that liposomal magnetofection may be a promising method that allows the targeting of gene therapy to lung cancer.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21683689     DOI: 10.1016/j.bbrc.2011.06.019

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

Review 1.  siRNA delivery to the lung: what's new?

Authors:  Olivia M Merkel; Israel Rubinstein; Thomas Kissel
Journal:  Adv Drug Deliv Rev       Date:  2014-06-05       Impact factor: 15.470

Review 2.  Magnetic nanoformulations for prostate cancer.

Authors:  Pallabita Chowdhury; Allison M Roberts; Sheema Khan; Bilal B Hafeez; Subhash C Chauhan; Meena Jaggi; Murali M Yallapu
Journal:  Drug Discov Today       Date:  2017-05-16       Impact factor: 7.851

Review 3.  In vivo gene delivery by nonviral vectors: overcoming hurdles?

Authors:  Yuan Zhang; Andrew Satterlee; Leaf Huang
Journal:  Mol Ther       Date:  2012-04-24       Impact factor: 11.454

Review 4.  Bench-to-bedside translation of magnetic nanoparticles.

Authors:  Dhirender Singh; JoEllyn M McMillan; Alexander V Kabanov; Marina Sokolsky-Papkov; Howard E Gendelman
Journal:  Nanomedicine (Lond)       Date:  2014-04       Impact factor: 5.307

Review 5.  Superparamagnetic iron oxide nanoparticle-based delivery systems for biotherapeutics.

Authors:  Hyejung Mok; Miqin Zhang
Journal:  Expert Opin Drug Deliv       Date:  2012-12-01       Impact factor: 6.648

Review 6.  Development of small RNA delivery systems for lung cancer therapy.

Authors:  Yu Fujita; Kazuyoshi Kuwano; Takahiro Ochiya
Journal:  Int J Mol Sci       Date:  2015-03-06       Impact factor: 5.923

7.  Co-delivery of doxorubicin and SATB1 shRNA by thermosensitive magnetic cationic liposomes for gastric cancer therapy.

Authors:  Zhao Peng; Chenxiao Wang; Erhu Fang; Xiaoming Lu; Guobin Wang; Qiang Tong
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

8.  Quantitative [Fe]MRI of PSMA-targeted SPIONs specifically discriminates among prostate tumor cell types based on their PSMA expression levels.

Authors:  Laurel O Sillerud
Journal:  Int J Nanomedicine       Date:  2016-01-20

9.  Cardiac-targeting magnetic lipoplex delivery of SH-IGF1R plasmid attenuate norepinephrine-induced cardiac hypertrophy in murine heart.

Authors:  Yiping Xu; Xuebiao Li; Minjian Kong; Daming Jiang; Aiqiang Dong; Zhonghua Shen; Qunjun Duan
Journal:  Biosci Rep       Date:  2014-10-02       Impact factor: 3.840

Review 10.  Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers.

Authors:  Md Emranul Karim; Kyi Kyi Tha; Iekhsan Othman; Mohammad Borhan Uddin; Ezharul Hoque Chowdhury
Journal:  Pharmaceutics       Date:  2018-05-26       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.